CCL2 and obesity disorder: The EDB bioactives have evoked different immune effects by controlling pro- and anti-inflammatory cytokines and mediators (Reactive oxygen species, NO, IL-6, TNF-α, MCP-1, IL-1, IL-8, IL-10, PGE2, COX-2, iNOS, INF-γ), that play a crucial role in acute and chronic low-grade inflammatory diseases associated with obesity, diabetes, dyslipidemia, cardiovascular disturbances, and neurodegenerative diseases [7,8,10,11,12,13,14,15,16].